Navigation Links
Worm studies shed light on human cancers
Date:4/21/2011

MADISON -- Research in the worm is shedding light on a protein associated with a number of different human cancers, and may point to a highly targeted way to treat them.

University of Wisconsin-Madison scientists were studying a worm protein called TFG-1, which is present in many cell types but whose exact role had never been understood. The scientists discovered that the protein controls key aspects of the movement, or secretion, of growth factors out of cells.

"TFG-1 has never been implicated in the secretory process before," says Dr. Anjon Audhya, an assistant professor of biomolecular chemistry in the School of Medicine and Public Health. "It turns out that humans carry a very similar protein, and we think it plays the same role in humans as in worms."

Reviewing the scientific literature, the researchers found that the gene encoding TFG in humans is fused to at least three other genes implicated in anaplastic large cell lymphoma, papillary thyroid carcinoma and extraskeletal chondrosarcoma. The fusions occur when two broken or rearranged pieces of DNA combine to form a "chimeric" gene with completely distinct properties.

Audhya's studies of TFG-1 in the worm led him to develop a model that explains how TFG fusions may stimulate cancer in humans. As reported in the current issue of Nature Cell Biology (Advanced Online Publication), he proposes that abnormal levels of growth factor secretion may produce a rich micro-environment that helps tumors form and thrive. "We think certain properties of TFG lead it to be a very effective precursor oncogene," he says.

Normally, a growth factor primed to leave a cell is encompassed by a sac, or vesicle, and then transported from one structure inside the cell to anotherendoplasmic reticulum (ER) to Golgibefore it leaves the cell and discharges into the extracellular space.

Through their genetic studies, the Wisconsin researchers found that TFG-1 in the worm controls vesicle formation and secretion out of the ER.

"We found TFG-1 lies at the interface between the ER and the Golgi, in a scaffolding structure called the ER exit site, where it regulates the formation of vesicles carrying their critical cargo," Audhya says.

The research revealed the precise location where TFG-1 does its work and the mechanism by which it spurs unchecked activity.

The scientists demonstrated that human TFG also functions at ER exit sites, which contain a characterized scaffolding protein called Sec16, and likely regulates secretion of multiple cargoes out of cells.

"In the case of one fusion gene, TFG-NTRK-1, the concentrated non-stop activity of NTRK-1 at ER exit sites may cause the first steps that can transform a normal cell into a cancer cell," Audhya says.

The TFG fusions offer a direct target for future "designer" therapies.

"If you identified patients who have fusion genes that express chimeric proteins, you could create a drug that affects only those proteins," he says, adding that TFG fusions leading to chimeric proteins do not exist in healthy people.

Excited about the possibility that their basic science investigations may be applied to several areas of clinical medicine, the researchers have also begun studying TFG as it relates to B-cell development and the secretion of antibodies.


'/>"/>

Contact: Dian Land
dj.land@hosp.wisc.edu
608-261-1034
University of Wisconsin-Madison
Source:Eurekalert

Related medicine news :

1. UC studies show marijuana has therapeutic value, reports to legislature
2. Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies
3. Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis
4. COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology
5. Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
6. Most Drug Studies Dont Help Docs Pick Best Treatment
7. Gays, Lesbians Excluded From Some Medical Studies
8. Studies Show Significant Increases of C. Difficile Infections (CDI)
9. Studies examine Third Eye Retroscope during colonoscopy
10. Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation
11. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... ... An inventor from Salisbury, N.C., knows the difficulties involved with leech therapy. "I ... to keep leeches in place during therapy," she said. "That’s why I came up ... to keep a leech in place on the skin during therapy. It prevents the ...
(Date:7/26/2017)... ... ... Six greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the ... of blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives ... to have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood ...
(Date:7/26/2017)... ... July 26, 2017 , ... It may be hard to ... accessible to people in the third world. Diseases that many developed countries consider rare ... who don't have access to vaccines. , On an upcoming segment of "Success Files", ...
(Date:7/26/2017)... , ... July 27, 2017 , ... It's time to sign up for ... with great benefits," says Kathy Heshelow, founder of Sublime Naturals and author of numerous books ... essential oil each month, mailed by the 5th. , Two items are ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 The ... treat rare nervous system diseases, has concluded a worldwide license ... the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing ... in a Phase 2 study conducted in Europe ... the United States ...
(Date:7/24/2017)... , July 24, 2017  Diplomat Pharmacy, Inc. ... will release its second quarter 2017 operating results on ... conference call to follow at 5:00 p.m. ET. ... may listen to a live broadcast of the conference ... and referencing participant code 51641230 approximately 15 minutes prior ...
(Date:7/21/2017)... July 21, 2017  Endo International plc (NASDAQ: ... comprehensive review of its manufacturing network, the Company will ... facilities in Huntsville, Alabama . The ... over the next 12 to 18 months. The ... declining volumes of commoditized products and these restructuring actions ...
Breaking Medicine Technology: